vs

Side-by-side financial comparison of Arcutis Biotherapeutics, Inc. (ARQT) and WW INTERNATIONAL, INC. (WW). Click either name above to swap in a different company.

WW INTERNATIONAL, INC. is the larger business by last-quarter revenue ($184.3M vs $129.5M, roughly 1.4× Arcutis Biotherapeutics, Inc.). Arcutis Biotherapeutics, Inc. runs the higher net margin — 13.4% vs -30.5%, a 44.0% gap on every dollar of revenue. On growth, Arcutis Biotherapeutics, Inc. posted the faster year-over-year revenue change (81.5% vs -4.5%). Over the past eight quarters, Arcutis Biotherapeutics, Inc.'s revenue compounded faster (70.1% CAGR vs -7.4%).

Arcutis Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies for immune-mediated dermatological diseases. Its core product portfolio targets conditions including psoriasis, atopic dermatitis, and alopecia areata, primarily serving patients and healthcare providers across the United States, addressing unmet needs in the dermatology care segment.

WW International, Inc., formerly Weight Watchers International, Inc., is a global company headquartered in the U.S. that offers weight loss and maintenance, fitness, and mindset services such as the Weight Watchers comprehensive diet program. Founded in 1963 by Queens, New York City homemaker Jean Nidetch, WW's program has three options as of 2019: online via its mobile app and website, coaching online or by phone, or in-person meetings.

ARQT vs WW — Head-to-Head

Bigger by revenue
WW
WW
1.4× larger
WW
$184.3M
$129.5M
ARQT
Growing faster (revenue YoY)
ARQT
ARQT
+86.0% gap
ARQT
81.5%
-4.5%
WW
Higher net margin
ARQT
ARQT
44.0% more per $
ARQT
13.4%
-30.5%
WW
Faster 2-yr revenue CAGR
ARQT
ARQT
Annualised
ARQT
70.1%
-7.4%
WW

Income Statement — Q2 FY2026 vs Q3 FY2025

Metric
ARQT
ARQT
WW
WW
Revenue
$129.5M
$184.3M
Net Profit
$17.4M
$-56.3M
Gross Margin
91.0%
72.2%
Operating Margin
14.2%
5.8%
Net Margin
13.4%
-30.5%
Revenue YoY
81.5%
-4.5%
Net Profit YoY
-21.8%
EPS (diluted)
$0.13
$-5.63

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARQT
ARQT
WW
WW
Q2 26
$129.5M
Q1 26
$105.4M
Q4 25
$129.5M
Q3 25
$99.2M
$184.3M
Q2 25
$81.5M
Q1 25
$65.8M
$186.6M
Q4 24
$71.4M
$184.4M
Q3 24
$44.8M
$192.9M
Net Profit
ARQT
ARQT
WW
WW
Q2 26
$17.4M
Q1 26
$-11.3M
Q4 25
$17.4M
Q3 25
$7.4M
$-56.3M
Q2 25
$-15.9M
Q1 25
$-25.1M
$-72.6M
Q4 24
$-10.8M
$25.1M
Q3 24
$-41.5M
$-46.2M
Gross Margin
ARQT
ARQT
WW
WW
Q2 26
91.0%
Q1 26
90.7%
Q4 25
91.0%
Q3 25
91.2%
72.2%
Q2 25
90.8%
Q1 25
86.6%
71.2%
Q4 24
90.3%
69.7%
Q3 24
87.7%
67.1%
Operating Margin
ARQT
ARQT
WW
WW
Q2 26
14.2%
Q1 26
-8.6%
Q4 25
14.2%
Q3 25
8.6%
5.8%
Q2 25
-17.9%
Q1 25
-37.3%
-10.8%
Q4 24
-10.7%
19.6%
Q3 24
-87.3%
-20.2%
Net Margin
ARQT
ARQT
WW
WW
Q2 26
13.4%
Q1 26
-10.7%
Q4 25
13.4%
Q3 25
7.5%
-30.5%
Q2 25
-19.5%
Q1 25
-38.1%
-38.9%
Q4 24
-15.1%
13.6%
Q3 24
-92.8%
-23.9%
EPS (diluted)
ARQT
ARQT
WW
WW
Q2 26
$0.13
Q1 26
$-0.09
Q4 25
$0.14
Q3 25
$0.06
$-5.63
Q2 25
$-0.13
Q1 25
$-0.20
$-0.91
Q4 24
$-0.09
$0.34
Q3 24
$-0.33
$-0.58

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARQT
ARQT
WW
WW
Cash + ST InvestmentsLiquidity on hand
$42.9M
$170.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$189.5M
$323.0M
Total Assets
$433.0M
$968.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARQT
ARQT
WW
WW
Q2 26
$42.9M
Q1 26
$34.8M
Q4 25
$42.9M
Q3 25
$47.1M
$170.1M
Q2 25
$72.7M
Q1 25
$53.1M
$236.3M
Q4 24
$71.3M
$53.0M
Q3 24
$134.9M
$57.2M
Total Debt
ARQT
ARQT
WW
WW
Q2 26
Q1 26
Q4 25
$109.0M
Q3 25
$108.5M
Q2 25
$108.0M
Q1 25
$107.6M
Q4 24
$107.2M
$1.4B
Q3 24
$204.6M
$1.4B
Stockholders' Equity
ARQT
ARQT
WW
WW
Q2 26
$189.5M
Q1 26
$189.6M
Q4 25
$189.5M
Q3 25
$158.1M
$323.0M
Q2 25
$139.0M
Q1 25
$142.7M
$-1.2B
Q4 24
$157.5M
$-1.1B
Q3 24
$156.6M
$-1.1B
Total Assets
ARQT
ARQT
WW
WW
Q2 26
$433.0M
Q1 26
$460.0M
Q4 25
$433.0M
Q3 25
$371.0M
$968.8M
Q2 25
$352.4M
Q1 25
$344.1M
$696.9M
Q4 24
$348.9M
$550.3M
Q3 24
$437.4M
$562.4M
Debt / Equity
ARQT
ARQT
WW
WW
Q2 26
Q1 26
Q4 25
0.58×
Q3 25
0.69×
Q2 25
0.78×
Q1 25
0.75×
Q4 24
0.68×
Q3 24
1.31×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARQT
ARQT
WW
WW
Operating Cash FlowLast quarter
$8.4M
Free Cash FlowOCF − Capex
$8.4M
FCF MarginFCF / Revenue
4.6%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$44.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARQT
ARQT
WW
WW
Q2 26
Q1 26
Q4 25
$26.2M
Q3 25
$-1.8M
$8.4M
Q2 25
$324.0K
Q1 25
$-30.4M
$15.0M
Q4 24
$-748.0K
$4.6M
Q3 24
$-34.7M
$16.5M
Free Cash Flow
ARQT
ARQT
WW
WW
Q2 26
Q1 26
Q4 25
Q3 25
$8.4M
Q2 25
$246.0K
Q1 25
$-31.0M
$15.0M
Q4 24
$4.5M
Q3 24
$-34.8M
$16.4M
FCF Margin
ARQT
ARQT
WW
WW
Q2 26
Q1 26
Q4 25
Q3 25
4.6%
Q2 25
0.3%
Q1 25
-47.1%
8.0%
Q4 24
2.4%
Q3 24
-77.8%
8.5%
Capex Intensity
ARQT
ARQT
WW
WW
Q2 26
Q1 26
Q4 25
0.0%
Q3 25
0.0%
0.0%
Q2 25
0.1%
Q1 25
0.9%
0.0%
Q4 24
0.0%
0.1%
Q3 24
0.3%
0.1%
Cash Conversion
ARQT
ARQT
WW
WW
Q2 26
Q1 26
Q4 25
1.51×
Q3 25
-0.24×
Q2 25
Q1 25
Q4 24
0.18×
Q3 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons